September MIMS Update

We look at some of the recent changes to the medicines landscape, with new indications and contraindications  New Indications Dapagliflozin (propanediol monohydrate) (Forxiga) is now indicated in adults for the treatment of symptomatic heart failure independent of left ventricular ejection fraction, as an adjunct to standard of care therapy. Dupilumab (Dupixent) is now indicated for